CXCL13

CXCL13, also known as C-X-C motif chemokine ligand 13, is a small cytokine protein alternatively termed B lymphocyte chemoattractant (BLC) or B cell-attracting chemokine 1 (BCA-1). It specifically binds to the G protein-coupled receptor CXCR5, orchestrating immune cell migration and lymphoid tissue organization. Functionally, CXCL13 drives chemotaxis of B cells and follicular helper T cells (Tfh), facilitating germinal center formation and tertiary lymphoid structure development in chronic inflammation. Its expression is tightly regulated in lymphoid organs but becomes aberrantly elevated in pathological contexts, including autoimmune disorders and lymphoproliferative diseases.
The CXCL13/CXCR5 axis activates downstream signaling pathways such as PI3K/AKT, MAPK/ERK, and JAK/STAT, modulating cell survival, proliferation, and cytokine production. Clinically, CXCL13 overexpression correlates with rheumatoid arthritis, multiple sclerosis, and lymphoma progression, particularly follicular lymphoma. Emerging therapeutic strategies target this pathway using monoclonal antibodies (e.g., anti-CXCL13 mAbs) and small-molecule CXCR5 antagonists, with several candidates in Phase I/II trials for autoimmune conditions. Additionally, CXCL13 serves as a biomarker for disease activity monitoring and immunotherapy response prediction in oncology.